Sartorius Stedim Biotech (SDMHF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Sartorius and Sartorius Ted in Biotech conference call on the first quarter 2025. I would like to remind you that all participants will be in listen-only mode and the conference has been recorded. This call is scheduled for 60 minutes. The presentation will be followed by Q&A session. In order to give all participants the opportunity to ask their question, we ask that the number of questions per person be limited to two. In addition, and in the interest of all participants, questions with the same content will only be answered once. You can register for questions at any time by pressing star and one. At this time, it's my pleasure to hand over to Dr. Joachim Kretschburg. Please go ahead, sir. Thank you very much for the introduction, and hello and welcome to our conference call on the Q1 results of Sartorius AG as well as Sartorius State in Biotech. Today, I'm together with Florian Funk, our CFO, as well as with René Faber, the president of our bioprocessing division, as well as the CEO of Sartorius State in Biotech, and also Alexandra Gatzemeier, the president of our lab division as she will walk you through the slide on the most recently announced acquisition of MATEC. So let me start with walking you through the highlights of the first quarter of 2025. We think we are off to a good start, a very good start into the year 2025. Pretty much development has been as expected. That means very much driven by a very healthy business with consumables in both divisions, but particularly in bioprocess solutions, where sales revenue is up in total by 10%, but strong double-digit growth in consumables, whereas the business with equipment remains rather muted as expected. And this has a stronger impact, of course, on the left division becaus...